In a recent speech, Democratic presidential nominee Joe Biden reaffirmed his position that people convicted of low-level drug offenses should be forced into rehabilitation in order to stay out of jail and get their records cleared.
While the former vice president seems to view the policy as a progressive alternative to incarceration, many drug reform advocates feel mandatory treatment reinforces misconceptions about substance misuse, and they point out that the efficacy of forced rehabilitation programs are scientifically questionable.
“Anybody who gets convicted of a drug crime—not one that is in terms of massive selling, but consumption—they shouldn’t go to prison. They should go to mandatory rehabilitation,” Biden said at a campaign event in Kenosha, Wisconsin last week. “Instead of building more prisons, as I’ve been proposing for some time, we build rehabilitation centers.”
“Mandatory. They’ve got to go to mandatory rehab, but it’s not part of the record when they get out if they finish it,” he said, adding that having a criminal record often prevents people from obtaining housing, financial aid for school and other public benefits.
It’s not clear whether Biden feels that people with low-level marijuana convictions should similarly be subject to mandatory rehabilitation. He’s proposed decriminalizing cannabis possession, but theoretically the rehab policy could fit within the framework he’s envisioning for a decriminalization policy that stops short of full legalization, which he opposes. Marijuana Moment reached out to his campaign for clarification, but a representative did not immediately respond.
In any case, mandatory rehabilitation is not the policy of choice for most drug reform advocates.
“Coerced treatment will inevitably result in forcing people who do not have substance use disorders or who would naturally recover into services,” Maritza Perez, director of national affairs at Drug Policy Action, told Marijuana Moment in response to Biden’s comments. “The overwhelming majority of people who use drugs do not develop a substance use disorder. Of those that do, most recover without participating in any formalized treatment or recovery services.”
“Additionally, mandatory treatment can have a net-widening effect, continuing to trap people under an alternative form of state surveillance,” she said. “Instead we must expand access to substance use disorder treatment and other support services that are attractive and affordable to increase voluntary treatment where appropriate. Biden’s proposal would merely waste resources that could be used for people who actually want and could benefit from treatment.”
Biden just said he’d push for mandatory rehab for drug possession, with the charge cleared if you complete the program. This isn’t reform. Possession does not mean addiction.
— Radley Balko (@radleybalko) September 3, 2020
This isn’t the only policy where Biden and drug reform advocates don’t see eye-to-eye. The nominee remains opposed to marijuana legalization despite supermajority support among voters. Instead, he supports decriminalizing cannabis possession, legalizing medical marijuana, expunging prior convictions and letting states set their own policies.
A senior adviser to Biden also said recently that his administration would pursue decriminalization and automatic expungements for prior marijuana convictions if he is elected.
Biden’s vice presidential running mate Sen. Kamala Harris (D-CA) similarly raised eyebrows in drug policy circles in a recent interview, lamenting racial disparities in cannabis enforcement without acknowledging her own record as a prosecutor who oversaw thousands of marijuana cases. Despite her past efforts to campaign against marijuana legalization in California as a candidate for state attorney general, she’s now the lead Senate sponsor of a bill to federally legalize cannabis. But despite her newfound support, Harris has indicated that she won’t be proactively pushing Biden to adopt a pro-legalization stance.
Earlier this year, Biden and Sen. Bernie Sanders (I-VT) established a criminal justice task force that issued various recommendations on policies they feel should be adopted. Advocates hoped the panel would push the former vice president to back legalization, but that didn’t materialize.
Meanwhile, the Democratic National Committee’s (DNC) platform committee rejected an amendment to make legalization a 2020 party plank. Some suspect this was because the panel didn’t want to endorse a policy that’s at odds with that of the nominee.
Democratic lawmakers have expressed confidence that Congress will deliver on legalization regardless of the Biden administration position on the issue.
House Democratic leadership recently announced that the chamber will vote its version of Harris’s comprehensive legalization bill later this month, setting the stage for a potential conflict with Biden if he’s asked to respond.
Sen. Ed Markey (D-MA), who recently won his primary battle against Rep. Joe Kennedy III (D-MA), said last month that legalization will be at the forefront of the congressional agenda in 2021 if Biden and Harris are elected. He also said during a separate interview in July that Congress will advance marijuana reform regardless of Biden’s stance.
Congressional Cannabis Caucus cochair Rep. Barbara Lee (D-CA), who was among the DNC platform committee members who surprisingly voted against the legalization amendment, said last week that the former vice president is going to need to evolve on marijuana policy and support legalization.
On the Republican side of the election, President Trump’s reelection campaign has been consistently attacking Biden over his record authoring punitive anti-drug laws in the Senate. They’ve cast him as an “architect” of the drug war while attempting to frame Trump as the criminal justice reform candidate. That’s despite the fact that the president’s administration has taken several hostile actions on the marijuana front that stop short of a full-scale crackdown on businesses in legalized states.
Last month, the president also urged Republicans not to place marijuana legalization initiatives on state ballots out of concern that it will increase Democratic turnout in elections.
Photo courtesy of Flickr/Marc Nozell.
Virginia Has Sealed 64,000 Marijuana Distribution Charges Since Legalization Took Effect This Summer
“These aren’t just numbers and there are families attached.”
By Ned Oliver, Virginia Mercury
Virginia has sealed records documenting more than 64,000 misdemeanor marijuana distribution charges since the state legalized the drug in July.
The figure came out Thursday during a meeting of the legislature’s Cannabis Oversight Commission.
Officials said the records were scrubbed from the state’s criminal record database, which is used by employers like school boards, state agencies and local governments to screen employees.
The state had already sealed 333,000 records detailing charges of simple possession last year after the state reduced the offense to a civil infraction on par with a traffic offense, said Shawn G. Talmadge, the Deputy Secretary of Public Safety and Homeland Security.
Lawmakers directed the state to expand that effort when they voted to broadly legalize recreational use of marijuana earlier this year.
The legislature also agreed to a broader expungement reform that will automatically seal other misdemeanor charges, including underage possession of alcohol, use of a fake ID, petit larceny, trespassing and disorderly conduct. Talmadge said those charges will remain in the system until the state finishes updating the software it uses to track criminal records.
“As of right now, the process is proceeding,” he said.
The Virginia Joint Commission on Cannabis Oversight is meeting now. You can find the agenda and links to livestream and to provide public comment at https://t.co/f1wsPn7SV7
— Jennifer McClellan (@JennMcClellanVA) October 14, 2021
Members of the oversight commission also heard from two advocates who urged them to move fast to address people currently imprisoned for marijuana offenses—a category of people the legalization legislation passed this year did not address.
Chelsea Higgs Wise, the leader of the advocacy group Marijuana Justice, and Gracie Burger, with the Last Prisoner Project, said Department of Corrections data suggests there are currently 10 people being held solely on serious marijuana charges.
They said it remains unknown how many more are being held because of marijuana related probation violations.
“These aren’t just numbers and there are families attached,” Burger said.
DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone
The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year.
In a notice scheduled to be published in the Federal Register on Monday, the agency said there’s been a “significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes,” and it wants authorized manufacturers to meet that growing demand.
DEA had already massively upped its proposed 2021 quota for cannabis and psilocybin last month, but now it’s calling for significantly larger quantities of research-grade marijuana and a broader array of psychedelics to be manufactured in 2022.
It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT. What especially stands out in the notice is MDMA. The agency is proposing an enormous 6,300 percent boost in the production of that drug—from just 50 grams in 2021 to 3,200 grams in the coming year—as research into its therapeutic potential continues to expand.
LSD would see a 1,150 percent increase, up to 500 grams of the potent psychedelic.
Marijuana itself would get a 60 percent boost under DEA’s proposal, up to 3.2 million grams in 2022 from the 2 million grams last year.
Here’s a visualization of the proposed quota increase from 2021 to 2022 for marijuana and cannabis extracts:
For all other THC, psilocybin, psilocyn and MDMA:
And for other psychedelic substances like LSD, mescaline and DMT:
DEA said in the Federal Register notice that it has been receiving and approving additional applications to “grow, synthesize, extract, and manufacture dosage forms containing specific schedule I hallucinogenic substances for clinical trial purposes” to achieve these ambitious quotas.
“DEA supports regulated research with schedule I controlled substances, as evidenced by increases proposed for 2022 as compared with aggregate production quotas for these substances in 2021,” the agency said, adding that it working “diligently” to process and approve marijuana manufacturers applications in particular, as there’s currently only one farm at the University of Mississippi that’s permitted to cultivate the plant for research.
“Based on the increase in research and clinical trial applications, DEA has proposed increases in 3,4- Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxymethamphetamine (MDMA), 5-Methoxy-N,N-dimethyltryptamine, Dimethyltryptamine, Lysergic acid diethylamide (LSD), Marihuana, Marihuana Extract, Mescaline, Psilocybin, Psilocyn, and All Other Tetrahydrocannabinols to support manufacturing activities related to the increased level of research and clinical trials with these schedule I controlled substances.”
Here are the exact numbers for the proposed 2021 and 2022 quotas:
|All other tetrahydrocannabinol||1,000||2,000|
A 30-day public comment period will be open after the notice is formally published on Monday.
It’s difficult to overstate just how significant the proposed 2022 increases are, but it’s certainly true that scientific and public interest in marijuana and psychedelics has rapidly increased, with early clinical trials signaling that such substances show significant therapeutic potential.
National Institute on Drug Abuse (NIDA) Director Nora Volkow told Marijuana Moment in a recent interview that she was encouraged by DEA’s previous proposed increase in drug production quota. She also said that studies demonstrating the therapeutic benefits of psychedelics could be leading more people to experiment with substances like psilocybin.
Advocates and experts remain frustrated that these plants and fungi remain in the strictest federal drug category in the first place, especially considering the existing research that shows their medical value for certain conditions.
A federal appeals court in August dismissed a petition to require the DEA to reevaluate cannabis’s scheduling under the Controlled Substances Act. However, one judge did say in a concurring opinion that the agency may soon be forced to consider a policy change anyway based on a misinterpretation of the therapeutic value of marijuana.
Separately, the Washington State attorney general’s office and lawyers representing cancer patients recently urged a federal appeals panel to push for a DEA policy change to allow people in end-of-life care to access psilocybin under state and federal right-to-try laws.
Image element courtesy of Kristie Gianopulos.
Supreme Court Won’t Hear Case On Legalizing Safe Drug Consumption Sites, But Activists Are Undeterred
The U.S. Supreme Court (SCOTUS) has rejected a request to hear a case on the legality of establishing safe injection sites where people can use illicit drugs in a medically supervised environment.
The justices announced on Tuesday that they decided against taking up the case raised by the nonprofit Safehouse, despite the pleas of attorneys general from 10 states and D.C. who recently filed amici briefs urging the court’s involvement.
Representatives from 14 cities and counties, as well as the mayor of Philadelphia, which is at the center of the current case, also filed briefs in support of the case in recent days.
Safehouse was set to launch a safe consumption site in Philadelphia before being blocked by a legal challenge from the Trump administration. It filed a petition with the nation’s highest court in August to hear the case.
But while the Supreme Court declined to take action—and the Biden administration passed up its voluntary opportunity to weigh in at this stage, which may well have influenced the justices’ decision—activists say the battle will continue at a lower federal court level, where the administration will have to file briefs revealing its position on the issue.
Disappointed but not surprised U.S. Supreme Court declined to hear our case. We’re pursuing our claims in federal court. As that litigation proceeds, Biden administration will have to take a position, which it avoided by waiving its right to respond to our Supreme Court petition.
— Safehouse (@SafehousePhilly) October 13, 2021
“We were disappointed that the government chose not to respond to our petition,” Safehouse Vice President Ronda Goldfein told Filter. “They said, ‘We’re going to waive our right to respond,’ [and] the Supreme Court declined to review our case. Ordinarily that sounds like the end of the road—but in our case we are still pursuing our claims in a different venue.”
That venue will be the the federal district court in Philadelphia, where activists plan to submit multiple arguments related to religious freedom and interstate commerce protections. The Biden administration will be compelled to file a response in that court by November 5.
“If they don’t respond, they lose,” Goldfein said.
A coalition of 80 current and former prosecutors and law enforcement officials—including one who is President Joe Biden’s pick for U.S. attorney of Massachusetts—previously filed a brief urging the Supreme Court to take up Safehouse’s safe injection case.
Fair and Justice Prosecution, the group that coordinated the amicus brief, also organized a tour of Portugal for 20 top prosecutors in 2019 so they could learn about the successful implementation of the country’s drug decriminalization law.
If the Supreme Court were to have taken the case and rule in favor of Safehouse, it could have emboldened advocates and lawmakers across the country to pursue the harm reduction policy.
The governor of Rhode Island signed a bill in July to establish a safe consumption site pilot program where people could test and use currently illicit drugs in a medically supervised environment. It became the first state in the country to legalize the harm reduction centers. It’s not clear whether the Department of Justice will seek to intervene to prevent the opening of such facilities in that state.
Massachusetts lawmakers advanced similar legislation last year, but it was not ultimately enacted.
A similar harm reduction bill in California, sponsored by Sen. Scott Wiener (D), was approved in the state Senate in April, but further action has been delayed until 2022.